ao-252
Brain Metastases From Solid Tumors
A2A Pharmaceuticals Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
102 Active assets in the Brain Metastases From Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB Iambic Therapeutics, Inc | Phase 4 | BB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BB |
Trastuzumab Deruxtecan Baptist Health South Florida | Phase 4 | BB |
Icotinib Betta Pharmaceuticals Co., Ltd. | Phase 3 | BB |
Capecitabine Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | BB |
View all 50 →
Same molecule, other indications
ao-252 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →